GPFA
ATOS icon

Game Plan Financial Advisors’s Atossa Therapeutics ATOS Stock Holding History

Game Plan Financial Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-667
Closed -$11K – 95
2022
Q2 		$11K Buy
+667
New +$10.5K 0.01% 96

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Game Plan Financial Advisors's ATOS Position: Q3 2022 in Review

Game Plan Financial Advisors sold out of Atossa Therapeutics (ATOS) in Q3 2022, closing a stake of 667 shares — an estimated $11K sold.

Game Plan Financial Advisors first reported a position in ATOS in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 56 funds tracked by Wall St. Rank hold ATOS as of Q3 2022.

  • Game Plan Financial Advisors reported no remaining Atossa Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Game Plan Financial Advisors sold 667 Atossa Therapeutics shares in Q3 2022, an estimated $11K.
  • Game Plan Financial Advisors first reported a position in Atossa Therapeutics in Q2 2022 and held it in 1 quarter.
  • Game Plan Financial Advisors's Atossa Therapeutics position peaked at $11K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2022.

Based on Game Plan Financial Advisors's 13F filing for Q3 2022, filed 3 Nov 2022.